O ur objective was to validate our estimates from our original model 1 and re-evaluate the cost-effectiveness of Spleen Australia, the Australian post-splenectomy registry, 2 using our original model with updated parameters based on advances in the literature and experience of the registry over the past decade.
The spleen has major roles in maintaining red cell integrity and immune function including antibody production and opsonisation of bacteria. Where splenic function is impaired; for example, functional hyposplenism, splenectomy or congenital asplenism, immune function is impaired. This puts the patient at a significant risk of infections including overwhelming post-splenectomy infection (OPSI), malaria, babesia, Capnocytophagia carnimorsus and Bordetella holmesii.
OPSI is a syndrome of fulminant invasive infection that can lead to death within 48 hours despite aggressive treatment. OPSI has a reported prevalence of 1 in 500 splenectomised patients, 3 with a mortality rate observed to range from 50% to 70%. 4, 5 Although international guidelines vary slightly, 2,6-8 overall they address three principles of prevention: immunisation, chemoprophylaxis and patient education. In Australia, Spleen Australia guidelines recommend the following management strategies:
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• Immunisation -Recommendations include initial and ongoing booster vaccination against Streptococcal pneumoniae, Neisseria meningitidis and Haemophilus influenzae type b (HiB), and annual administration of the influenza vaccination.
• Chemoprophylaxis -All patients are recommended daily penicillin or amoxicillin (or a macrolide if allergic) for at least three years after splenectomy, and life-long antibiotics if they are at high risk for infections (e.g. immunocompromised patients). Patients should also carry a supply of antibiotics (commonly, amoxicillin three grams) to use in an emergency in the case of severe illness.
• Education -Patients and their family members should be informed about the risk of infections, the importance of immunisations and antibiotics, and the need to present early to medical services in the event of sudden severe illness. Patients should know to seek travel advice prior to travel and be aware of the infectious risk with animal bites. It is recommended that patients always carry a medical alert in the form of a bracelet or wallet-sized card in case they present with illness and an impaired state of consciousness.
Initial modelling and updates on cost effectiveness from the first 10 years of a spleen registry In terms of outcomes, the number of invasive pneumococcal disease (IPD) cases in the asplenic population in Victoria in 2010-2015 ranged from two to nine per annum (mean 5.6). 13 Where vaccination was known, 57%
were fully vaccinated and 43% were not. A study in Victoria suggested that registration is associated with a reduction in vaccinepreventable disease rates of 69%. 14 The costs of treating a case of OPSI remains highly variable, with cases notified to Spleen Australia costing up to $280,000 (in 2014).
In 2016, we combined the registry experience to date and findings of the two recent Australian studies 11, 12 to update the parameters of our original model 1 and assess implications for effectiveness and costeffectiveness estimates.
Methods
We performed a cost-effectiveness analysis from a healthcare perspective using a decision tree model with Markov nodes comparing a cohort of 1,000 registry participants to a cohort of 1,000 people with asplenia or hyposplenism not covered by a registry. 1 The Markov nodes are annual health states. Cohort age on entry was set to the mean age of patients registered at the time of initial model construction (48 years). The impact of the registry was assessed through uptake rates of vaccination, chemoprophylaxis and education, on outcomes of OPSI and mortality. Costs and outcomes were evaluated over the initial two years of registration (when costs are expected to be high) and the remaining lifetime of the cohort (approximately 60 years). All costs and outcomes that occur in the future are discounted at 5%, so the expression of costs and outcomes is in terms of their net present values.
Similar to our original model, we chose to focus on OPSI as the primary outcome measure. The model was evaluated for two OPSI-related outcomes: the number of cases of OPSI prevented (the difference in number of cases of OPSI estimated for the cohort with and without a registry) and the number of years of life gained with (compared to without) a registry. This is directly related to the cases of OPSI prevented, as the only sources of mortality in the model cohorts are the background life expectancy (common across the two cohorts) and the mortality following OPSI.
We updated our model parameters to reflect the newly available evidence (see Table 1 ). 11, 12 There is no additional evidence on OPSI risk or the effectiveness of interventions (with or without a registry) on OPSI risk reduction. We retained the model parameters from the initial model for OPSI risk reduction with intervention, as the study performed by El Alfy et al. 15 remains the best available estimate for reduction in OPSI risk with varying uptake of interventions to date ( Table 1 ).
The original estimates of resources required for initial education remained valid and were updated to 2016 Australian dollars to reflect general inflation and current treatment recommendations ( Table 1 ). All cost estimates were based on the costs experienced in the local hospital and costs experienced by the registry. The increased scale of operation of the registry (beyond expectations of the original model) has resulted in greater distribution of annual fixed administration costs ($250,000) distributed among 5,000 participants ($50/participant). Conversely, vaccine costs have increased due to additions to the recommended vaccines. The cost of a treating a case of OPSI was based on local hospital cost data from known OPSI cases. The cost of treating a case of OPSI in hospital remains highly variable and available estimates remain within the original range, so we maintained the original estimate.
Results
Baseline estimates and associated ranges of uncertainty for each required category of model input are shown in Table 1 . Costeffectiveness results are presented in Table 2 . Costs and benefits of the registry are shown for both the first two years of implementation and over the lifetime of the cohort (approximately 60 years).
In the first two years, the additional cost of the registry was $ There have been no studies comparing cost-effectiveness of Australian clinical registries, other than a report by the Australian Commission on Safety and Quality in Health Care that assessed the cost-effectiveness of five Australian clinical registries. 17 This report concluded that these five clinical registries provided significant positive return on investment but declared that not every clinical registry that is established will be cost-effective. In our evaluation, we show that although using this registry is not cost-saving, it does appear to be cost-effective when viewed over a cohort lifetime and is associated with improved patient health benefits. We initially anticipated this service to be a state-wide registry and evaluated its costeffectiveness in this scale. In performing this re-evaluation, we realised that not only did we over-estimate compliance to interventions, but we also underestimated the scale and growth of the registry. However, despite inaccuracies in our initial modelling estimates, our results revealed that the initial model accurately predicted that the registry would be a cost-effective intervention. 1 In addition, we chose OPSI as our primary outcome measure. Although OPSI is the most important infectious outcome, risk of other infectious outcomes including but not limited to malaria, Capnocytophagia carnimorsus and Bordetella holmesii are likely to be reduced with registry use. Thus, limiting our assessment to OPSI as the primary outcome is likely to have missed some benefits of the registry.
Although this re-evaluation has incorporated recent evidence and data, it also highlights the limited breadth and depth of the literature regarding OPSI risk reduction with varying intervention use and the efficacy of such interventions. Estimates of costeffectiveness remain most sensitive to the accuracy of these efficacy data. We also still have limited data on the proportion of patients with asplenia or hyposplenism who are not registered in Victoria, Tasmania and Queensland. Vaccine uptake rates appear higher among registered cohorts 11 compared to non-registered cohorts, 12 suggesting a mechanism for lower rates of preventable infections in those on the spleen registry. 14 
Conclusions
Use of a registry appears to have a causal impact on increasing compliance rates to management interventions and reduction in adverse infectious outcomes. Our reevaluation finds that although the registry is not cost-saving, it does appear to be costeffective.
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Implications for public health
Practice recommendations
It is logical to expand the registry to host all states and territories within Australia to optimise uptake of preventive health interventions and thus infectious outcomes in patients with asplenia or hyposplenism, since many of the capital costs of development of intellectual property, online support systems and registry software are fixed. In addition, clinicians should actively register patients with asplenia or hyposplenism to the healthcare service to improve adherence to management and prevention of adverse infectious outcomes.
Research recommendations
Rates of compliance in registrants over time would provide better long-term estimates of effectiveness and cost-effectiveness. In addition, greater precision over estimates of OPSI prevalence with varying levels of uptake of preventive interventions, and the effectiveness of interventions -particularly the use of long-term chemoprophylaxiswould reduce uncertainty over estimates of registry effectiveness and cost-effectiveness.
